By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Regeneron Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ...

Multiple myeloma is a type of blood cancer that affects plasma cells, a kind of white blood cell found in the bone marrow.

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of ...